| Translated title of the contribution | Risks of adverse events with therapies for age-related macular degeneration: a response |
|---|---|
| Original language | English |
| Pages (from-to) | 124 - 125 |
| Number of pages | 2 |
| Journal | Archives of Ophthalmology |
| Volume | 130(1) |
| DOIs | |
| Publication status | Published - Jan 2012 |
Research Groups and Themes
- BTC (Bristol Trials Centre)
Research output
- 2 Citations
- 1 Article (Academic Journal)
-
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial
IVAN Study Investigators, Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J. & Wordsworth, S., Jul 2012, In: Ophthalmology. 119, 7, p. 1399-1411 13 p.Research output: Contribution to journal › Article (Academic Journal) › peer-review
725 Citations (Scopus)
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver